518 related articles for article (PubMed ID: 29480637)
21. [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
Dupic G; Collangettes D; Dillies AF; Calvet L; Tournilhac O; Bay JO; Mahammedi H
Bull Cancer; 2015 Dec; 102(12):1010-9. PubMed ID: 26607453
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws.
Klingelhöffer C; Zeman F; Meier J; Reichert TE; Ettl T
J Craniomaxillofac Surg; 2016 Oct; 44(10):1694-1699. PubMed ID: 27591091
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a surgical treatment of denosumab-related osteonecrosis of the jaws.
Pichardo SE; van Merkesteyn JP
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):272-8. PubMed ID: 27234854
[TBL] [Abstract][Full Text] [Related]
24. Dental implications of bisphophonate-related osteonecrosis.
Saldanha S; Shenoy VK; Eachampati P; Uppal N
Gerodontology; 2012 Sep; 29(3):177-87. PubMed ID: 22486711
[TBL] [Abstract][Full Text] [Related]
25. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
[TBL] [Abstract][Full Text] [Related]
26. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J
J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739
[TBL] [Abstract][Full Text] [Related]
27. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents.
Rodriguez-Lozano FJ; Oñate-Sánchez RE
Med Oral Patol Oral Cir Bucal; 2016 Sep; 21(5):e595-600. PubMed ID: 27475683
[TBL] [Abstract][Full Text] [Related]
28. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
Takaoka K; Kishimoto H
Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
[TBL] [Abstract][Full Text] [Related]
29. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature.
Gavaldá C; Bagán JV
Med Oral Patol Oral Cir Bucal; 2016 May; 21(3):e260-70. PubMed ID: 26827066
[TBL] [Abstract][Full Text] [Related]
30. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate-related osteonecrosis of the jaws--a case report.
Kamoh AK; Ogle O
Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
[TBL] [Abstract][Full Text] [Related]
33. Osteonecrosis of Jaws in Prostate Cancer Patients Treated With Antiresorptive Drugs: A Review.
Vaddi A; Manuballa S; Andreana S
Compend Contin Educ Dent; 2021 Feb; 42(2):62-67; quiz 68. PubMed ID: 33735578
[TBL] [Abstract][Full Text] [Related]
34. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2.
Coropciuc RG; Grisar K; Aerden T; Schol M; Schoenaers J; Politis C
Br J Oral Maxillofac Surg; 2017 Oct; 55(8):787-792. PubMed ID: 28760314
[TBL] [Abstract][Full Text] [Related]
35. [Bisphosphonate-related osteonecrosis of the jaw].
Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Halpern LR; Adams DR
Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
[TBL] [Abstract][Full Text] [Related]
37. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
[TBL] [Abstract][Full Text] [Related]
38. Osteonecrosis of the Jaw.
Hamdy RC
J Clin Densitom; 2017; 20(1):1-2. PubMed ID: 28259260
[No Abstract] [Full Text] [Related]
39. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
40. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
